CalciMedica (CALC) CEO Rachel Leheny Buys $149K of Stock

CalciMedica, Inc. (CALC on the NasdaqCM) Chief Executive Officer Dr. A. Rachel Leheny Ph.D. acquired 186,729 shares of her company's stock. According to a Form 4 filed with the Securities and Exchange Commission, Leheny purchased the shares on June 25, 2026, at an average price of $0.80 per share, making the total transaction worth $149,383.2.

A Coordinated Insider Buying Spree at CalciMedica

This purchase represents a significant personal commitment from the chief executive, but it is even more striking when viewed alongside her team's actions. On that very same day, a group of five insiders, including Leheny, together purchased nearly 2 million shares of CalciMedica. This concerted buying effort injected over $1.5 million into the company's equity, showing a strong collective vote of confidence in the biotech firm's pipeline and future direction.

A Wave of Insider Purchases

The other participants in this buying wave were also high-ranking figures at the company. Chief Business Officer Eric Roberts purchased 186,729 shares for $149,383.2. Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares for $99,588.8. Meanwhile, Fred Middleton picked up 248,972 shares valued at $199,177.6, and Robert Wilson made the largest purchase of the group, acquiring 1,182,621 shares for a total of $946,096.8. All of these transactions were completed on June 25, 2026, at the identical price of $0.80 per share, and none of them were executed under a pre-planned Rule 10b5-1 trading agreement.

CalciMedica Stock Performance and Valuation

On Monday, CalciMedica shares were trading at $0.99. The stock has experienced a volatile year, trading within a wide 52-week range of $1.86 to $36.00. The current price of $0.99 is below its 52-week low and is trading well below its 50-day moving average of $3.03 and its 200-day moving average of $7.75. This means the insiders stepped in to buy when the stock was near its absolute lowest point of the year, potentially seeing the beaten-down share price as a discount.

Recent Earnings and Financial Health

Financially, CalciMedica is still in its clinical stage and does not currently generate traditional profits, resulting in an unprofitable status and no meaningful P/E ratio. The company reported a loss of -$6.85 per share (EPS) and has a return on equity of -3.657%. Investors looking ahead should note that the company's next earnings date is listed as August 11, 2025.

What Wall Street Thinks of CalciMedica

Wall Street analysts maintain an optimistic outlook for the biotechnology firm. On August 20, 2026, Guggenheim started its coverage on CalciMedica, giving it a Buy rating and setting a price target of $9.00. Across the broader analyst community, the stock holds a consensus target mean price of $50.00, with three analysts offering opinions. The individual price targets range from a low of $30.00 to a high of $75.00, suggesting that analysts believe the stock has substantial room to run from its current levels.

Developing Critical Care Therapies

CalciMedica is a clinical-stage biopharmaceutical business based in La Jolla, California. The company focuses on developing therapies for diseases caused by cellular damage and severe inflammatory reactions. Its main drug candidate is Auxora, an intravenous treatment designed to block calcium channels to treat critical conditions such as acute pancreatitis, acute kidney injury, and severe pneumonia.

What to Watch at CALC

Moving forward, investors should watch how CalciMedica's clinical trials progress and monitor whether insiders continue to buy shares. It is important to remember that insider transactions are backward-looking and do not guarantee future stock performance, though they do provide a window into what the company's leadership thinks about its valuation.